Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PainChek Ltd ( (AU:PCK) ) has provided an update.
PainChek Ltd has successfully demonstrated the clinical and economic benefits of its PainChek Adult App in a Scottish care trial, highlighting its potential to significantly improve patient outcomes and reduce healthcare costs. The trial, funded by the Scottish Government, showed notable reductions in falls, medication use, and care dependency, projecting a potential £66 million savings for the Scottish healthcare system. With commercial licenses already covering over 42,000 aged care beds in the UK, PainChek is well-positioned to capitalize on this data, enhancing its market positioning and unlocking further growth opportunities in the global hospital market.
More about PainChek Ltd
PainChek Ltd is a developer of a smart device-based pain assessment and monitoring application. The company operates within the healthcare technology industry, focusing on providing innovative solutions for pain management. Their primary product, the PainChek Adult App, is designed to improve clinical outcomes and reduce medication dependency in aged care settings. PainChek is actively expanding its market presence in the UK, particularly within the aged care sector.
Average Trading Volume: 1,931,874
Technical Sentiment Signal: Buy
Current Market Cap: A$105.2M
See more insights into PCK stock on TipRanks’ Stock Analysis page.